We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 20, 2020

Venetoclax + Bendamustine–Rituximab or Venetoclax + Bendamustine–Obinutuzumab in CLL



Additional Info

Disclosure statements are available on the authors' profiles:

Venetoclax Plus Bendamustine–Rituximab or Bendamustine–Obinutuzumab in Chronic Lymphocytic Leukemia: Final Results of a Phase 1b Study (GO28440)
Haematologica 2020 Oct 29;[EPub Ahead of Print], S Stilgenbauer, F Morschhauser, CM Wendtner, G Cartron, M Hallek, B Eichhorst, MF Kozloff, T Giever, G Lozanski, Y Jiang, H Huang, DS Pignataro, W Schary, K Humphrey, M Mobasher, G Salles

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading